{"filing":{"accession_number":"0001919246-26-000110","cik":"0001919246","ticker":"PTHS","company_name":"Pelthos Therapeutics Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-12","primary_document":"pths-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1919246/000191924626000110/pths-20260812.htm"},"events":[{"id":27457,"run_id":25030,"accession_number":"0001919246-26-000110","anchor_item_number":"4.02","event_type":"restatement","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"The Audit Committee concluded on August 12, 2026 that the Company's previously issued condensed consolidated financial statements for Q1 2026 should no longer be relied upon due to a misapplication of ASC 820 (Fair Value Measurements) in valuing convertible debt. The restatement involves material adjustments: a $15.8 million increase in convertible debt liabilities, a $14.8 million increase in non-cash fair value expense, and a $14.8 million increase in accumulated deficit. The filing explicitly states \"the Company will restate the condensed consolidated financial statements for the Affected Period\" and discloses a material weakness in internal controls over fair value measurement of Level 3 convertible debt instruments.","company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29012,"accession_number":"0001919246-26-000110","item_number":"4.02","item_title":"(a). Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.","event_type":"restatement","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The Audit Committee concluded on August 12, 2026 that the Company's previously issued condensed consolidated financial statements for Q1 2026 should no longer be relied upon due to a misapplication of ASC 820 (Fair Value Measurements) in valuing convertible debt. The restatement involves material adjustments: a $15.8 million increase in convertible debt liabilities, a $14.8 million increase in non-cash fair value expense, and a $14.8 million increase in accumulated deficit. The filing explicitly states \"the Company will restate the condensed consolidated financial statements for the Affected Period\" and discloses a material weakness in internal controls over fair value measurement of Level 3 convertible debt instruments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:03:38.018388+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29012,"accession_number":"0001919246-26-000110","item_number":"4.02","item_title":"(a). Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.","event_type":"restatement","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The Audit Committee concluded on August 12, 2026 that the Company's previously issued condensed consolidated financial statements for Q1 2026 should no longer be relied upon due to a misapplication of ASC 820 (Fair Value Measurements) in valuing convertible debt. The restatement involves material adjustments: a $15.8 million increase in convertible debt liabilities, a $14.8 million increase in non-cash fair value expense, and a $14.8 million increase in accumulated deficit. The filing explicitly states \"the Company will restate the condensed consolidated financial statements for the Affected Period\" and discloses a material weakness in internal controls over fair value measurement of Level 3 convertible debt instruments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:03:38.018388+00:00","company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","filing_date":"2026-08-13"}]}